Tom Powles, Chair of Bart’s Cancer Institute, shared a post on X:
“There are currently 4 global randomized III trials exploring novel ADCs in UC. 2 of them explore different TROP2/TOP1 ADC (like SG which failed for OS in UC).
SAC-TMT alone 3rd line.
D-DXD in combo with platinum 2nd line.
IzaBren looks more novel (HER1+3) while the DV/IO study has already been done successfully in China. How many of these will make a difference.”
Other articles featuring Tom Powles on OncoDaily.